Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, ...

The healthcare industry can’t afford to be stagnant. Cost pressures, operational pressures and real human lives are at stake ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

In 2025, AI [artificial intelligence] will play a larger role in driving payer operational improvements and offer health insurers a more comprehensive view of member health.